

S3 Table. Patient characteristics of matched cohort (n=66)

Characteristic	<i>ATM</i> ^{wt} <i>BRCA</i> ^{wt} (n=33)	<i>ATM</i> ^{mt} <i>BRCA</i> ^{wt} (n=5)	<i>ATM</i> ^{wt} <i>BRCA</i> ^{mt} (n=16)	<i>ATM</i> ^{mt} <i>BRCA</i> ^{mt} (n=6)	p-value
Age (yr)	52 (27-80)	43 (39-57)	55 (36-71)	46 (26-66)	0.149
Sex					0.567
Male	12 (36.4)	3 (60.0)	8 (36.4)	1 (16.7)	
Female	21 (63.6)	2 (40.0)	14 (63.6)	5 (83.3)	
Primary site					0.310
Unknown	0	1 (20.0)	0	0	
Breast	1 (3.0)	1 (20.0)	2 (9.1)	1 (16.7)	
Lung	13 (39.4)	0	8 (36.4)	1 (16.7)	
GI tract	12 (36.4)	2 (40.0)	6 (27.3)	2 (33.3)	
Genitourinary	7 (21.2)	1 (20.0)	5 (22.7)	2 (33.3)	
Skin	0	0 (0)	1 (4.5)	0 (0)	
EQD2 (Gy)					0.051
< 45	13 (39.4)	0	14 (63.6)	3 (50.0)	
≥ 45	20 (60.6)	5 (100)	8 (36.4)	3 (50.0)	
Pre-RT chemotherapy					0.423
Cytotoxic chemo	27 (81.8)	5 (100)	15 (68.2)	4 (66.7)	
Target agents	2 (6.1)	0	4 (18.2)	2 (33.3)	
None	4 (12.1)	0	3 (13.6)	0	

Values are presented as mediana (range) or number (%). EQD2, equivalent dose in 2 Gy; RT, radiotherapy.